|
ETS1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.634400E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.301200E-01 |
| Normal-vs-Stage2 |
4.210400E-01 |
| Normal-vs-Stage3 |
1.598970E-01 |
| Normal-vs-Stage4 |
1.641390E-01 |
| Stage1-vs-Stage2 |
9.822300E-02 |
| Stage1-vs-Stage3 |
3.079500E-03 |
| Stage1-vs-Stage4 |
2.997700E-02 |
| Stage2-vs-Stage3 |
4.875800E-01 |
| Stage2-vs-Stage4 |
4.476800E-01 |
| Stage3-vs-Stage4 |
8.528800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.321600E-01 |
| Normal-vs-AfricanAmerican |
6.332200E-01 |
| Normal-vs-Asian |
6.785800E-01 |
| Caucasian-vs-AfricanAmerican |
8.265200E-01 |
| Caucasian-vs-Asian |
2.515400E-01 |
| AfricanAmerican-vs-Asian |
3.911000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.601000E-01 |
| Normal-vs-Female |
5.676800E-01 |
| Male-vs-Female |
4.412600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.133200E-01 |
| Normal-vs-Age(41-60Yrs) |
3.330800E-01 |
| Normal-vs-Age(61-80Yrs) |
7.172300E-02 |
| Normal-vs-Age(81-100Yrs) |
8.988000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.164600E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.7506000000005E-05 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.001200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.343960E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.898200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.981800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.415400E-04 |
| Classical-VS-Follicular |
2.615800E-02 |
| Classical-VS-Other |
1.041170E-01 |
| Classical-VS-Normal |
7.984400E-01 |
| Tall-VS-Follicular |
1.272420E-01 |
| Tall-VS-Other |
6.911400E-01 |
| Tall-VS-Normal |
3.264100E-02 |
| Follicular-VS-Other |
2.381800E-01 |
| Follicular-VS-Normal |
3.033000E-01 |
| Other-VS-Normal |
2.113600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.463200E-01 |
| Normal-vs-N1 |
3.888200E-01 |
| N0-vs-N1 |
9.315400E-01 |
|
|
